New combo therapy aims to tame devastating nerve attacks
NCT ID NCT07410039
First seen Feb 26, 2026 · Last updated May 09, 2026 · Updated 7 times
Summary
This study tests whether adding eculizumab to standard steroid therapy helps people with neuromyelitis optica spectrum disorder (NMOSD) recover better from sudden attacks. It involves 200 adults with a specific antibody (AQP4-positive) who are in the early phase of an attack. The goal is to see if the combination reduces disability and improves quality of life compared to steroids alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the First Medical Center of Chinese PLA General Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.